News Sentiment

MESO sentiment intelligence

Mesoblast Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 63 Constructive news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 15.44 Week of 10 Jul 2026
Weighted tone 63/100

Constructive news tone

Market reaction News confirmed by price

Constructive news tone is being confirmed by positive weekly price action.

Primary event Market update

78/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+7.4% over one week, +10.8% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?

Market Reaction

News confirmed by price

73/100 confidence

Constructive news tone is being confirmed by positive weekly price action.

Primary event Market update 78/100 classification
One-week reaction 7.4% Price confirming higher
Trend fit Trend inactive 10.8% over four weeks
Fair value 46.7% Materially above fair value
Sentiment-trend disagreement Positive but stretched

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 30
Neutral 27
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 9
simplywall.st 7
grafa.com 4
MT Newswires 3
GuruFocus 3
Kalkine Media 3
Simply Wall Street 3

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 19
Analyst action 7
Guidance 2
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Stock Titan Direct company coverage

Mesoblast Limited (MESO) sees 278,571 director options lapse in July

Mesoblast Limited (MESO) filed a Form 6-K reporting that 278,571 options belonging to Dr. Silviu Itescu, CEO and Executive Director, lapsed on July 7, 2026. This lapse was due to a previously achieved duplicative milestone, and no consideration was exchanged. Dr. Itescu's total o

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 10:11
Source
Stock Titan
Stock Titan Direct company coverage

Mesoblast (NASDAQ: MESO) reaches 300 patients in Phase 3 CLBP trial

Mesoblast Limited announced it has enrolled 300 patients in its pivotal Phase 3 trial (MSB-DR004) for chronic low back pain associated with degenerative disc disease, meeting its target for a well-powered study. The trial aims to confirm the durable pain reduction seen previously

Tone
Positive 71/100
Event
Analyst action
Published
14 Jul 2026 12:11
Source
Stock Titan
grafa.com Direct company coverage

Mesoblast reaches 300-patient Phase 3 trial target

Mesoblast has successfully enrolled 300 patients in its Phase 3 clinical trial for rexlemestrocel-L, a therapy targeting chronic low back pain. The company anticipates releasing top-line results by mid-2027 and believes the treatment has the potential to generate over $10 billion

Tone
Positive 72/100
Event
Earnings
Published
14 Jul 2026 08:51
Source
grafa.com
Kalkine Direct company coverage

Is Mesoblast (ASX:MSB) Trading Within Its 52-Week Price Range?

Mesoblast (ASX:MSB) shares declined by 0.21% to AUD 2.345 during the latest trading session, with trading volumes below average. The stock's intraday range was AUD 2.285 to AUD 2.380, and it has a market capitalization of AUD 2.89 billion. Mesoblast continues to trade within its

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 05:42
Source
Kalkine
grafa.com Direct company coverage

Australia's Mesoblast reaches target of 300 trial patients

Australian biotechnology company Mesoblast has successfully enrolled 300 patients in its pivotal Phase 3 trial for chronic low back pain. This milestone, which led to a rise in the company's share price, is crucial for validating its new therapy and supporting future regulatory a

Tone
Positive 71/100
Event
Analyst action
Published
14 Jul 2026 02:27
Source
grafa.com
Investing.com South Africa Direct company coverage

Mesoblast reaches 300-patient enrollment in back pain trial By Investing.com

Mesoblast Limited has successfully enrolled over 300 patients in its Phase 3 trial for chronic low back pain using rexlemestrocel-L, a significant milestone that led to a 13% stock increase. The trial, designed in agreement with the FDA, aims to measure pain reduction and other i

Tone
Positive 73/100
Event
Market update
Published
14 Jul 2026 01:42
Source
Investing.com South Africa
Stock Titan Direct company coverage

Mesoblast Tests One Injection for Chronic Low Back Pain

Mesoblast (Nasdaq: MESO; ASX: MSB) announced it has reached its target of 300 treated patients in its pivotal Phase 3 trial (MSB-DR004) for chronic low back pain (CLBP) associated with degenerative disc disease. The trial, utilizing rexlemestrocel-L, aims to confirm durable pain

Tone
Positive 74/100
Event
Analyst action
Published
14 Jul 2026 00:42
Source
Stock Titan
Market source Direct company coverage

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast Limited announced it has achieved its target of treating 300 patients in its pivotal Phase 3 trial (MSB-DR004) for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm durable pain reduction using rexlemestrocel-L, building o

Tone
Positive 75/100
Event
Analyst action
Published
13 Jul 2026 22:35
Source
Market source
GuruFocus Direct company coverage

Mesoblast (MESO) Sees 6.2% Increase in Share Value

Mesoblast (MESO) saw a 6.2% increase in its share value, reaching $16.40, driven by growing investor confidence in its allogeneic cellular medicines for severe inflammatory conditions. Despite positive investor sentiment and insider buys, the company’s valuation metrics, includin

Tone
Positive 67/100
Event
Market update
Published
13 Jul 2026 14:40
Source
GuruFocus
Investing.com Direct company coverage

Australia shares higher at close of trade; S&P/ASX 200 up 0.03%

Australian shares concluded Monday's trading session higher, with the S&P/ASX 200 index rising by 0.03%. Gains were primarily driven by the Telecoms Services, Consumer Discretionary, and Financials sectors. Notable gainers included Mesoblast Ltd, Stanmore Coal, and Ampol Ltd, whi

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 06:40
Source
Investing.com
Kalkine Direct company coverage

Mesoblast Jumps 7% (ASX:MSB): Is Fresh Momentum Building Around This ASX Biotech Stock?

Mesoblast Limited (ASX: MSB) experienced a notable 7.14% surge on July 13, 2026, reaching $2.40, amidst a declining broader Health Care sector. This gain occurred without any immediate company-specific announcement, shortly after Mesoblast reported US$115 million in Ryoncil net r

Tone
Positive 61/100
Event
Market update
Published
13 Jul 2026 04:11
Source
Kalkine
Moomoo Direct company coverage

Mesoblast Moved to Buy From Speculative Buy by Bell Potter

Bell Potter has upgraded Mesoblast (ASX:MSB) from a "Speculative Buy" to a "Buy" rating, reflecting increased confidence in the company. This upgrade suggests a more positive outlook from the analyst firm regarding Mesoblast's potential.

Tone
Positive 71/100
Event
Analyst action
Published
13 Jul 2026 02:40
Source
Moomoo
grafa.com Direct company coverage

Mesoblast reports $115 million Ryoncil revenue in FY2026

Mesoblast reported preliminary Ryoncil revenue of US$115 million for the full fiscal year ended June 30, 2026, exceeding initial projections. The company recorded US$36 million in revenue for the fourth quarter and anticipates continued growth in fiscal 2027 as adoption expands a

Tone
Positive 90/100
Event
Earnings
Published
10 Jul 2026 12:10
Source
grafa.com
Stock Titan Direct company coverage

Mesoblast (MESO) reports US$115M first full-year Ryoncil sales and strong Q4

Mesoblast (MESO) reported preliminary net revenue of US$36 million for Ryoncil® in the fourth quarter and US$115 million for its first full commercial year ending June 30, 2026. This exceeds initial projections, with strong uptake in major U.S. pediatric centers. The company also

Tone
Positive 74/100
Event
Earnings
Published
10 Jul 2026 09:39
Source
Stock Titan
Barchart.com Direct company coverage

Degenerative Disc Disease Market Statistics Expected to Experience Major Growth by 2036, According to DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan, Histogen

The global Degenerative Disc Disease (DDD) market is projected to experience substantial growth, increasing from approximately USD 1.2 billion in 2025 to nearly USD 7.2 billion by 2036, with a CAGR of 19.04%. This expansion is attributed to advancements in regenerative therapies,

Tone
Positive 70/100
Event
Market update
Published
10 Jul 2026 07:42
Source
Barchart.com
scanx.trade Direct company coverage

Ryoncil revenue hits US$36M in Q4, FY26 total at US$115M

Mesoblast Limited announced strong Ryoncil net revenue, reaching US$36 million in Q4 FY26 and US$115 million for the full fiscal year, exceeding projections due to high U.S. pediatric demand. CEO Dr. Silviu Itescu confirmed the company's robust capital position, fueled by revenue

Tone
Positive 93/100
Event
Earnings
Published
10 Jul 2026 03:10
Source
scanx.trade
grafa.com Direct company coverage

Mesoblast delivers full year revenue of US$115M

Mesoblast (ASX:MSB) reported a full-year net revenue of US$115 million, exceeding initial projections due to strong sales of its approved cellular medicine. The company also recorded US$36 million in net revenue for the fourth quarter and plans to use a new five-year credit facil

Tone
Positive 74/100
Event
Earnings
Published
10 Jul 2026 01:01
Source
grafa.com
Sharecafe Direct company coverage

Mesoblast Reports Strong RYONCIL® Revenue, Exceeding Projections

Mesoblast Limited (ASX:MSB) announced strong financial results for its product Ryoncil®, with Q4 net revenue of US$36 million and a full-year net revenue of US$115 million, exceeding initial projections. Ryoncil® is the first FDA-approved mesenchymal stromal cell product for chil

Tone
Positive 93/100
Event
Earnings
Published
10 Jul 2026 00:10
Source
Sharecafe
Market source Direct company coverage

Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026

Mesoblast Limited announced Ryoncil® (remestemcel-L-rknd) achieved net revenue of US$36 million for the fourth quarter and US$115 million for the full year ended June 30, 2026. The company is pleased with Ryoncil's market uptake since its launch and anticipates continued revenue

Tone
Positive 73/100
Event
Earnings
Published
09 Jul 2026 20:30
Source
Market source
AD HOC NEWS Direct company coverage

Mesoblast Ltd outlook for regenerative medicine. MESO stock aligns long-term strategy

Mesoblast Ltd is a biotechnology company focused on developing regenerative cell therapies for serious inflammatory and cardiovascular diseases, with its MESO stock reflecting a long-term investment case in advanced biologics. The company's strategy involves a pipeline of allogen

Tone
Positive 72/100
Event
Guidance
Published
07 Jul 2026 19:09
Source
AD HOC NEWS